A unified 35-gene signature for both subtype classification and survival prediction in diffuse large B-cell Lymphomas

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-8

  Cai, Yu Dong ^a,d   Huang, Tao ^b,c   Feng, Kai Yan ^c   Hu, Lele ^a   Xie, Lu ^c  

^a SHANGHAI UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

^c SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; CANCER SURVIVAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; PREDICTION; SURVIVAL TIME; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS;

TUMOR MARKER;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77958573912     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012726     Document Type: Article

References (46)

1. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89: 3909-3918.
2. Veelken H, Vik Dannheim S, Schulte Moenting J, Martens UM, Finke J, et al. (2007) Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol 18: 931-939.
3. Berglund M, Thunberg U, Amini RM, Book M, Roos G, et al. (2005) Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 18: 1113-1120.
4. Lossos IS, Levy R (2003) Diffuse large B-cell lymphoma: insights gained from gene expression profiling. Int J Hematol 77: 321-329.
5. Turgeon ML (2005) Clinical hematology: theory and procedures. HagerstownMD: Lippincott Williams & Wilkins.
6. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
7. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105: 13520-13525.
8. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, et al. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105: 1851-1861.
9. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, et al. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350: 1828-1837.
10. Peng H, Long F, Ding C (2005) Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans Pattern Anal Mach Intell 27: 1226-1238.
11. Lenz G, Wright G, Dave SS, Xiao W, Powell J, et al. (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359: 2313-2323.
12. Friedman JH, Baskett F, Shustek LJ (1975) An algorithm for finding nearest neighbors. IEEE Trans Comput C-24: 1000-1006.
13. Qian Z, Cai YD, Li Y (2006) A novel computational method to predict transcription factor DNA binding preference. Biochem Biophys Res Commun 348: 1034-1037.
14. Huang T, Cui W, Hu L, Feng K, Li YX, et al. (2009) Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. PLoS One 4: e8126.
15. Huang T, Shi XH, Wang P, He Z, Feng KY, et al. (2010) Analysis and prediction of the metabolic stability of proteins based on their sequential features, subcellular locations and interaction networks. PLoS ONE 5: e10972.
16. Huang T, Tu K, Shyr Y, Wei CC, Xie L, et al. (2008) The prediction of interferon treatment effects based on time series microarray gene expression profiles. J Transl Med 6: 44.
17. Andersen PK, Gill RD (1982) Cox's Regression Model for Counting Processes: A Large Sample Study. The Annals of Statistics 10: 1100-1120.
18. Harrington DP, Fleming TR (1982) A Class of Rank Test Procedures for Censored Survival-Data. Biometrika 69: 553-566.
19. Huang T, Wang P, Ye ZQ, Xu H, He Z, et al. (2010) Prediction of Deleterious Non-Synonymous SNPs Based on Protein Interaction Network and Hybrid Properties. PLoS ONE 5: e11900.
20. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, et al. (2006) A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 210: 67-85.
21. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, et al. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100: 9991-9996.
22. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947.
23. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, et al. (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198: 851-862.
24. Goytain A, Hines RM, Quamme GA (2008) Functional characterization of NIPA2, a selective Mg2+ transporter. Am J Physiol Cell Physiol 295: C944-953.
25. Koch JG, Gu X, Han Y, El-Naggar AK, Olson MV, et al. (2007) Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome 18: 300-309.
26. Marinkovic D, Marinkovic T, Kokai E, Barth T, Moller P, et al. (2004) Identification of novel Myc target genes with a potential role in lymphomagenesis. Nucleic Acids Res 32: 5368-5378.
27. Chang JT, Nevins JR (2006) GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22: 2926-2933.
28. Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, et al. (2001) Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98: 945-951.
29. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, et al. (2000) BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13: 199-212.
30. Senga T, Iwamoto T, Humphrey SE, Yokota T, Taparowsky EJ, et al. (2002) Stat3-dependent induction of BATF in M1 mouse myeloid leukemia cells. Oncogene 21: 8186-8191.
31. Storlazzi CT, Mertens F, Nascimento A, Isaksson M, Wejde J, et al. (2003) Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet 12: 2349-2358.
32. Panagopoulos I, Storlazzi CT, Fletcher CD, Fletcher JA, Nascimento A, et al. (2004) The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer 40: 218-228.
33. Ammanamanchi S, Freeman JW, Brattain MG (2003) Acetylated sp3 is a transcriptional activator. J Biol Chem 278: 35775-35780.
34. Hung JJ, Wang YT, Chang WC (2006) Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription. Mol Cell Biol 26: 1770-1785.
35. Nicolas E, Morales V, Magnaghi-Jaulin L, Harel-Bellan A, Richard-Foy H, et al. (2000) RbAp48 belongs to the histone deacetylase complex that associates with the retinoblastoma protein. J Biol Chem 275: 9797-9804.
36. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, et al. (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92: 1300-1304.
37. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, et al. (2005) Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 94: 11-16.
38. Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, et al. (2003) Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 10: 333-338.
39. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, et al. (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28: 1714-1724.
40. Kallergi G, Agelaki S, Markomanolaki H, Georgoulias V, Stournaras C (2007) Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. Cell Physiol Biochem 20: 977-986.
41. Shim H, Lee H, Jeoung D (2006) Cancer/testis antigen cancer-associated gene (CAGE) promotes motility of cancer cells through activation of focal adhesion kinase (FAK). Biotechnol Lett 28: 2057-2063.
42. Lacoste J, Aprikian AG, Chevalier S (2005) Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility. Mol Cell Endocrinol 235: 51-61.
43. Baytel D, Shalom S, Madgar I, Weissenberg R, Don J (1998) The human Pim-2 proto-oncogene and its testicular expression. Biochim Biophys Acta 1442: 274-285.
44. Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, et al. (2005) Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 65: 276-286.
45. Gong J, Wang J, Ren K, Liu C, Li B, et al. (2009) Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell. J Surg Res 153: 17-22.
46. Yan B, Zemskova M, Holder S, Chin V, Kraft A, et al. (2003) The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 278: 45358-45367.